Sanofi SNY introduced that the FDA has accepted for assessment its supplemental biologics license utility (sBLA) in search of approval for its blockbuster inflammatory drug Dupixent (dupilumab) as an add-on therapy of uncontrolled moderate-to-severe bronchial asthma in youngsters aged six to 11
www.nasdaq.com
Sanofi's (SNY) Dupixent sBLA for Bronchial asthma Will get FDA Acceptance
